Login to Your Account



ArQule, Roche Enter Potential $276M Cancer Checkpoint Deal

By Randall Osborne


Monday, April 5, 2004
About seven months after completing its $25 million buyout of Cyclis Pharmaceuticals Inc., ArQule Inc. has leveraged the acquired Activated Checkpoint Therapy technology to nail down a deal with Roche that could be worth up to $276 million, plus royalties. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription